Tang Dongsheng, Chen Yue, Shi Yuye, Tao Hong, Tao Shandong, Zhang Quan'e, Ding Banghe, He Zhengmei, Yu Liang, Wang Chunling
Department of Hematology, The Huaian Clinical College of Xuzhou Medical University, Huai'an, China.
Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Front Oncol. 2022 Feb 10;12:817043. doi: 10.3389/fonc.2022.817043. eCollection 2022.
This study was conducted in order to study the clinical characteristics, prognostic factors, and treatment outcomes in patients with primary central nervous system lymphoma (PCNSL).
The data of a total of 5,166 PCNSL patients diagnosed between 2000 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database were obtained.
The mean age was 63.1 ± 14.9 years, with a male to female ratio of 1.1:1.0. The most common histologic subtype was diffuse large B-cell lymphoma (DLBCL) (84.6%). The 1-, 3-, and 5-year overall survival (OS) rates were 50.1%, 36.0%, and 27.2%, respectively, and the corresponding disease-specific survival (DSS) rates were 54.4%, 41.3%, and 33.5%, respectively. Multivariate analysis with Cox regression showed that race, sex, age, marital status, surgical resection, and chemotherapy were independent prognostic factors for OS and DSS, but radiotherapy was only for OS. Nomograms specially for DLBCL were established to predict the possibility of OS and DSS. The concordance index (C-index) values of OS and DSS were 0.704 (95% CI 0.687-0.721) and 0.698 (95% CI 0.679-0.717), suggesting the high discrimination ability of the nomograms.
Surgical resection and/or chemotherapy was favorably associated with better OS and DSS. However, radiotherapy was not beneficial for OS and DSS in the long term. A new predictive nomogram and a web-based survival rate calculator we developed showed favorable applicability and accuracy to predict the long-term OS for DLBCL patients specifically.
开展本研究以探讨原发性中枢神经系统淋巴瘤(PCNSL)患者的临床特征、预后因素及治疗结果。
获取了监测、流行病学和最终结果(SEER)数据库中2000年至2018年间诊断的共5166例PCNSL患者的数据。
平均年龄为63.1±14.9岁,男女比例为1.1:1.0。最常见的组织学亚型为弥漫性大B细胞淋巴瘤(DLBCL)(84.6%)。1年、3年和5年总生存率(OS)分别为50.1%、36.0%和27.2%,相应的疾病特异性生存率(DSS)分别为54.4%、41.3%和33.5%。Cox回归多因素分析显示,种族、性别、年龄、婚姻状况、手术切除和化疗是OS和DSS的独立预后因素,但放疗仅对OS有影响。建立了专门针对DLBCL的列线图以预测OS和DSS的可能性。OS和DSS的一致性指数(C指数)值分别为0.704(95%CI 0.687 - 0.721)和0.698(95%CI 0.679 - 0.717),表明列线图具有较高的辨别能力。
手术切除和/或化疗与更好的OS和DSS呈正相关。然而,从长期来看,放疗对OS和DSS并无益处。我们开发的一种新的预测列线图和基于网络的生存率计算器对预测DLBCL患者的长期OS显示出良好的适用性和准确性。